---
title: "HENLIUS's two products have been approved by the European Commission for the treatment of osteoporosis in specific populations and other indications"
description: "HENLIUS announced that its products BILDYOS and BILPREVDA have been approved by the European Commission for the treatment of osteoporosis in specific populations. This approval covers all EU member st"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258059688.md"
published_at: "2025-09-19T09:57:45.000Z"
---

# HENLIUS's two products have been approved by the European Commission for the treatment of osteoporosis in specific populations and other indications

> HENLIUS announced that its products BILDYOS and BILPREVDA have been approved by the European Commission for the treatment of osteoporosis in specific populations. This approval covers all EU member states as well as Iceland, Liechtenstein, and Norway, with indications including osteoporosis in high-risk postmenopausal women and men, bone loss in men with prostate cancer, and prevention of bone-related events in adults with advanced bone malignancies

HENLIUS (02696.HK) announced that the marketing authorization applications (MAAs) for its products BILDYOS and BILPREVDA have been approved by the European Commission. The trademarks for these products are registered by N.V. Organon in the EU. This approval means that the two products have received centralized marketing authorization in all EU member states as well as Iceland, Liechtenstein, and Norway.

The approved indications are for all indications for Prolia and XGEVA marketed in the EU, specifically:

The indication for BILDYOS is the treatment of osteoporosis in postmenopausal women and men at high risk of fractures; treatment of bone loss associated with hormone ablation in men with high-risk prostate cancer; and treatment of bone loss related to long-term systemic glucocorticoid therapy in adult patients at high risk of fractures.

The indications for BILPREVDA include the prevention of skeletal-related events in adults with advanced bone malignancies; and treatment of patients with giant cell tumors of the bone that are not amenable to surgical resection or may lead to severe functional impairment after surgical resection, including adults and skeletally mature adolescents

### Related Stocks

- [02696.HK - HENLIUS](https://longbridge.com/en/quote/02696.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Henlius Biotech Doses First Patient in Phase 1b/2 Trial of HLX43 Combination for Advanced Colorectal Cancer | Shanghai Henlius Biotech Inc. has initiated a phase 1b/2 clinical trial for HLX43, an anti-PD-L1 antibody-drug conjugate | [Link](https://longbridge.com/en/news/275577160.md) |
| Shanghai Henlius Biotech NDA for Denosumab Biosimilar Accepted by China NMPA | Shanghai Henlius Biotech Inc.'s New Drug Application for HLX14, a biosimilar of denosumab, has been accepted for review  | [Link](https://longbridge.com/en/news/268228062.md) |
| The gender pay gap will take 30 years to close, report says | A report by the Trades Union Congress (TUC) indicates that the gender pay gap will take 30 years to close, with women cu | [Link](https://longbridge.com/en/news/275988803.md) |
| As pressure mounted to release Epstein files, FBI employees compiled allegations against other men | As pressure mounted to release the Epstein files, FBI employees compiled allegations against men associated with Jeffrey | [Link](https://longbridge.com/en/news/275395734.md) |
| Hong Kong police arrest 2 over HK$300,000 watch theft on inbound flight | Hong Kong Police arrested two individuals for stealing a HK$300,000 watch from a passenger's backpack on an inbound flig | [Link](https://longbridge.com/en/news/275853880.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
